Prelude Therapeutics Cash Flow Statement (2023-2026) | PRLD

1Y3Y5Y7Y10YAll
Download Data
Cash Flow Statement Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter) -34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M
Share-based Compensation (Quarter) 5.55M6.10M5.93M3.77M3.83M3.81M2.42M1.84M2.00M
Gains from Sales and Divestitures (Quarter) 0.06M0.01M0.03M0.03M0.04M0.01M0.02M0.03M0.04M0.06M
Gains from Investment Securities (Quarter) 11.90M0.00M0.00M0.00M0.01M0.00M0.00M15.50M-0.04M0.58M
Non-cash Items (Quarter) 4.90M7.00M4.00M8.15M0.10M0.01M9.53M1.10M9.53M14.00M
Cash from Operations (Quarter) -31.79M-23.06M-27.30M-20.74M-34.23M-26.07M-19.11M23.12M-21.68M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter) 0.41M0.40M0.39M3.44M-0.08M0.85M-0.58M0.19M0.39M
Depreciation & Amortization (CF) (Quarter) 0.43M0.45M0.41M0.49M0.43M0.43M0.42M0.42M0.39M
Change in Working Capital
Change in Account Payables (Quarter) 0.63M1.08M-0.21M1.81M-1.91M-0.85M-2.43M1.27M-1.88M
Change in Accured Expenses (Quarter) -5.69M1.23M2.09M1.57M-3.97M1.87M-0.37M-0.52M-6.60M
Other Working Capital Changes (Quarter) -0.64M-0.19M-0.08M0.92M1.05M0.33M-0.29M34.44M0.07M
Investing Activities
Capital Expenditures (Quarter) 0.29M0.36M0.06M-0.70M0.05M0.02M
Change in Acquisitions & Divestments (Quarter) 37.00M34.36M42.79M29.50M71.70M36.20M40.09M6.40M8.50M
Cash from Investing Activities (Quarter) 31.22M26.12M10.73M22.12M62.19M11.52M40.09M-60.34M8.50M
Financing Activities
Other financing activities (Quarter) 5.55M6.10M5.93M3.83M3.81M2.42M11.91M0.29M
Cash from Financing Activities (Quarter) -0.01M0.06M-0.13M-0.03M-0.16M0.04M-0.01M24.94M-0.31M
Additional items
Change in Cash (Quarter) -0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M
Free Cash Flow (Quarter) -32.08M-23.42M-27.36M-20.04M-34.28M-26.09M-19.11M23.12M-21.68M
Net Cash Flow (Quarter) -0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M